Thus, whether the GnRH antagonist protocol leads to lower severe OHSS rates compared to the GnRH agonist protocol in PCOS patients with lower AMH and lower bLH/FSH levels is a point of confusion that has not been investigated by previous studies. This evidence concerns the gene BRD2 and ovarian hyperstimulation syndrome.